Summary & Overview
HCPCS Q4225: Amniobind or Dermabind, per square centimeter
HCPCS Level II code Q4225 designates Amniobind or Dermabind applied and billed per square centimeter as an add-on item in addition to a primary procedure. This code captures use of topical wound-binding matrices or biologic dressings that support tissue approximation and wound management, and is relevant for surgical and procedural settings where such adjunctive products are used. Nationally, accurate reporting of add-on supply codes supports clinical documentation, claims processing, and product utilization tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical role of the product, payer coverage considerations, common modifiers associated with add-on supplies, and where to locate related billing guidance. The publication summarizes benchmarks and coding guidance where available and highlights clinical contexts in which Q4225 is typically reported, such as operative wound management, outpatient procedural dressings, and emergency wound care. Data not available in the input is noted where applicable. The content is intended to inform billing staff, compliance teams, and clinical coders about the code’s purpose, typical settings, and the types of analyses and policy updates that readers can expect to consult.
Billing Code Overview
HCPCS Level II code Q4225 describes Amniobind or Dermabind topical/laboratory product, billed per square centimeter as an add-on supply to a primary procedure. It is used when a clinician or facility applies a biologic or synthetic wound-binding matrix measured by surface area to support tissue approximation or wound management.
Service Type: Topical wound-binding product / biologic dressing (supply add-on)
Typical Site of Service: Operating room, procedural suite, emergency department, or outpatient wound care clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual with a full-thickness or deep partial-thickness wound, donor-site wound, or chronic nonhealing ulcer requiring biologic topical wound matrix coverage to promote healing. The clinical workflow commonly occurs in an outpatient wound clinic, ambulatory surgery center, or hospital outpatient department. After wound assessment, debridement and hemostasis are performed; the clinician measures the wound area in square centimeters to determine the required amount of product. Q4225 (Amniobind or Dermabind, per square centimeter) is applied as an adjunctive topical biologic dressing layered over the wound bed and secured according to manufacturer instructions. The product is billed as an add-on supply in addition to the primary procedure (for example, excisional debridement, skin grafting, or surgical closure). Typical patient scenarios include: a diabetic foot ulcer undergoing sharp debridement and application of a biologic binding matrix; a venous stasis ulcer treated in clinic with wound bed preparation and topical amniotic/dermal matrix; or a surgical donor site receiving topical biologic to optimize epithelialization. Procedural documentation should include wound measurements (cm2), description of wound bed preparation, amount of Q4225 used (cm2), method of application, and concurrent primary procedure CPT code(s).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |